Cardiovascular Disease Doctors in Fort Gordon, GA Accepting Medicare

3 Cardiovascular Disease doctors found. Showing 1 - 3

Dr. Brian Christopher Pomerantz, M.D. Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 300 W Hospital Rd, Fort Gordon, GA 30905 Phone: 706-787-5811

Dr. Robert E Jeschke, D.O. Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 300 Hospital Road, Eisenhower Army Medical Center, Attn - Credentials, Fort Gordon, GA 30905 Phone: 706-787-2720    Fax: 706-787-8176

Dr. Susan Noe, M.D. Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 300 W Hospital Rd, Cardiology Clinic, Fort Gordon, GA 30905 Phone: 706-787-6922    Fax: 706-787-7767

News Archive

IMO announces availability of medical terminology products on iPhone/iPad platforms

Intelligent Medical Objects (IMO), the leading provider of medical vocabulary services, announces today the availability of its IMO Problem (IT) and IMO Procedure (IT) terminology products on the iPhone and iPad platforms.

Patrolling monocytes may play anti-cancer role in the lung

One goal of immunotherapy is to rally a patient's often over-burdened immune cells to effectively attack a tumor. Among foot soldiers on the immune front line is a subpopulation of white blood cells called "patrolling monocytes," whose job is to cruise the bloodstream, cart off cellular debris, and block invasion of a less benign population of inflammatory cells.

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

Scientists have long known the p53 protein suppresses tumors. However, a recent animal study by UC Davis researchers has uncovered a complicated relationship between p53 and another protein, Rbm38, highlighting how the body calibrates protein levels. Too much Rbm38 reduces p53 levels, increasing the risk of cancer.

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Read more Medical News

› Verified 6 days ago